Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Karl Belanger
Nomograms for Predicting Survival of Patients With Newly Diagnosed Glioblastoma: Prognostic Factor Analysis of EORTC and NCIC Trial 26981-22981/Ce.3
The Lancet Oncology
Oncology
Selective Incorporation of Iododeoxyuridine Into DNA of Hepatic Metastases Versus Normal Human Liver
Clinical Pharmacology and Therapeutics
Pharmacology
Related publications
Prognostic Nomogram for the Overall Survival of Patients With Newly Diagnosed Multiple Myeloma
BioMed Research International
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
Prognostic Nomograms and Aggtrmmns Scoring System for Predicting Overall Survival and Cancer‐specific Survival of Patients With Kidney Cancer
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma
Archives of Neurology
A 5-Gene Prognostic Nomogram Predicting Survival Probability of Glioblastoma Patients
Brain and Behavior
Behavioral Neuroscience
Controversies in the Treatment of Elderly Patients With Newly Diagnosed Glioblastoma
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Patients With Surgically Resected Intrahepatic Cholangiocarcinoma
Cancer Management and Research
Oncology
Association of Patterns of Care, Prognostic Factors, and Use of Radiotherapy–temozolomide Therapy With Survival in Patients With Newly Diagnosed Glioblastoma: A French National Population-Based Study
Journal of Neuro-Oncology
Cancer Research
Oncology
Neurology
Development and Validation of Nomograms for Predicting Survival in Patients With Non-Metastatic Colorectal Cancer
Oncotarget
Oncology
Plasma YKL-40 as a Biomarker for Bevacizumab Efficacy in Patients With Newly Diagnosed Glioblastoma in the Phase 3 Randomized AVAglio Trial
Oncotarget
Oncology
